Lucid Diagnostics (NASDAQ:LUCD) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Lucid Diagnostics (NASDAQ:LUCD) from a hold rating to a sell rating in a research note issued to investors on Saturday.

Several other research firms have also weighed in on LUCD. Ascendiant Capital Markets boosted their target price on shares of Lucid Diagnostics from $7.50 to $7.75 and gave the company a “buy” rating in a research note on Friday, June 6th. BTIG Research boosted their price objective on shares of Lucid Diagnostics from $2.00 to $2.50 and gave the company a “buy” rating in a research report on Friday, September 5th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $3.00 price objective on shares of Lucid Diagnostics in a research note on Wednesday, August 13th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $3.65.

Lucid Diagnostics Trading Down 0.9%

Shares of NASDAQ LUCD opened at $1.08 on Friday. The company has a market capitalization of $144.16 million, a price-to-earnings ratio of -0.91 and a beta of 1.24. Lucid Diagnostics has a twelve month low of $0.73 and a twelve month high of $1.80. The business has a 50 day simple moving average of $1.10 and a 200-day simple moving average of $1.24.

Insider Buying and Selling at Lucid Diagnostics

In other Lucid Diagnostics news, Director Dennis Matheis acquired 100,000 shares of Lucid Diagnostics stock in a transaction dated Wednesday, August 20th. The stock was acquired at an average cost of $1.02 per share, for a total transaction of $102,000.00. Following the completion of the transaction, the director owned 665,443 shares in the company, valued at approximately $678,751.86. This represents a 17.69% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 6.80% of the company’s stock.

Institutional Trading of Lucid Diagnostics

Several hedge funds have recently added to or reduced their stakes in LUCD. Berkshire Asset Management LLC PA acquired a new position in Lucid Diagnostics during the 1st quarter worth $30,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Lucid Diagnostics in the first quarter worth about $37,000. Quadrature Capital Ltd bought a new position in Lucid Diagnostics in the 2nd quarter valued at about $29,000. Cubist Systematic Strategies LLC bought a new position in Lucid Diagnostics in the 1st quarter valued at about $39,000. Finally, Traphagen Investment Advisors LLC acquired a new position in Lucid Diagnostics during the 2nd quarter valued at about $34,000. Institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.